MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

41.71 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
This Trend is Excellent News for Eli Lilly and Its Investors ↗
Eli Lilly and Novo Nordisk are vying for a new part of the weight loss drug market. 
Via The Motley Fool
News headline image
Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded? ↗
The company is still looking to bounce back after the beating it took in recent years. 
Via The Motley Fool
Topics Economy
News headline image
Eli Lilly's Momentum Looks Unstoppable -- but 1 Factor Could Change Everything ↗
The drugmaker has a lot riding on continued clinical progress. 
Via The Motley Fool
News headline image
3 Absurdly Cheap Growth Stocks to Buy Before the End of 2026 ↗
These stocks have been struggling lately, but they could be underrated buys in the long run. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst ↗
Demand for Novo Nordisk's new GLP-1 pill is rising quickly, while Eli Lilly's new pill faces an important headwind. 
Via The Motley Fool
News headline image
Could This New Opportunity Be Worth Billions for Novo Nordisk? ↗
The worst may be in the rearview mirror for the drugmaker. 
Via The Motley Fool
News headline image
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? ↗
Madrigal has a first-mover advantage in treating MASH, a type of fatty liver disease. 
Via The Motley Fool
News headline image
Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There. ↗
This company aims to serve a market heading toward $100 billion. 
Via The Motley Fool
News headline image
Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore? ↗
Shares of Novo Nordisk are trading 66% below their 2024 high, but is that enough to call them cheap? Maybe. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 of the Best Growth Stocks to Buy for Less Than $100 Right Now ↗
Netflix, Uber, and Novo Nordisk are all excellent, undervalued stocks to buy today. 
Via The Motley Fool
News headline image
Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock? ↗
The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions. 
Via The Motley Fool
News headline image
Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case. ↗
Investors always need to appreciate risk before buying into any clinical-stage biopharmaceutical company. 
Via The Motley Fool
News headline image
2 Stocks Down 8% or More That Are Screaming Buys Right Now ↗
You might regret ignoring these companies at current levels. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Should Eli Lilly Investors Be Worried About a Threat From Amylyx? ↗
Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate. 
Via The Motley Fool
News headline image
Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly? ↗
Novo Nordisk is leaning into convenience as it tries to regain its lead in the GLP-1 weight-loss space. 
Via The Motley Fool
News headline image
Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal ↗
Duquesne Family Office has beefed up its healthcare holdings. 
Via The Motley Fool
News headline image
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can ↗
Could this little-known biotech be a hidden gem? 
Via The Motley Fool
News headline image
2 Biotech Stocks Shaping Up for Major Breakouts ↗
Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts. 
Via MarketBeat
Topics ETFs
News headline image
A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
From Equity Insider
Via GlobeNewswire
News headline image
3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now ↗
Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations. 
Via The Motley Fool
News headline image
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk) ↗
They are way more than just GLP-1 stocks. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger ↗
The U.K.'s health regulator just approved Eli Lilly's new weight-loss pill, a huge win for the drug maker. 
Via The Motley Fool
News headline image
Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity ↗
The stock continues to look unstoppable. 
Via The Motley Fool
News headline image
Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating? ↗
It's yet another setback for the drugmaker. 
Via The Motley Fool
News headline image
Hims & Hers’ Revenue Beat Came With a Profitability Problem ↗
Hims & Hers topped Q2 revenue estimates and raised guidance, but missed EPS forecasts, posted a wider net loss, and faces an FTC lawsuit, leaving Wall Street cautious with a Hold rating. 
Via MarketBeat
Topics Earnings Lawsuit
News headline image
Novo Nordisk Stock: Buy or Sell? ↗
Sales of weight loss treatments have been incredible for Novo Nordisk. 
Via The Motley Fool
News headline image
Better Buy: Eli Lilly vs. Novo Nordisk ↗
Novo Nordisk is playing catch-up in the GLP-1 race. 
Via The Motley Fool
News headline image
Why Eli Lilly Topped the Market Today ↗
One of its more popular products just got the green light from a major national regulator. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story